Astria Therapeutics (ATXS) AI Stock Analysis

• Market Cap: $375.29M
• Dividend Yield: N/A
• Average Volume (3M): 232.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: N/A
• EPS Growth: 11.81%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 56,434,895
• 10 Day Avg. Volume: 248,891
• 30 Day Avg. Volume: 232,540
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.16
• 1Y Price Target: $30.17
• Price Target Upside: 346.30% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 44 Neutral
• Price Target: ―

Astria Therapeutics' stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.

Positive Factors

Clinical trials

Positive initial safety and efficacy results from the ALPHA-SOLAR study of navenibart in HAE patients were announced.

Financial performance

Astria's financial results showed a stronger EPS than estimated, ending the quarter with $259.2 million in cash.

Strategic partnerships

Astria announced a licensing agreement with Kaken Pharmaceutical, allowing Astria to receive up to $32 million in upfront and milestone payments.

Negative Factors

Clinical trial risks

The general liver delivery and editing approach of Intellia's ATTR-CM and HAE programs are the same, adding additional risk/questions to NTLA-002 as more patients are enrolled.

Market competition

There are many alternative safe, effective, and convenient options for HAE prophylaxis approved and in development, such as Astria's navenibart.

Astria Therapeutics Business Overview & Revenue Model

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

How the Company Makes Money

Astria Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and potential royalties on sales of successfully developed drugs. Additionally, Astria Therapeutics may receive funding through grants and research collaborations. The company's revenue model typically involves significant investment in research and development, with potential returns materializing upon regulatory approval and market launch of its therapies.

Astria Therapeutics Financial Statement Overview

Summary

Astria Therapeutics is in a pre-revenue stage with increasing net losses. A robust balance sheet with low leverage and high equity provides financial stability, but the absence of revenue and consistent cash outflows present significant financial risks.

Income Statement

Astria Therapeutics has consistently reported zero revenue over the years, reflecting its pre-revenue stage typical for biotechnology firms. The net losses have increased, with the net income showing a decline from -$26.2M in 2019 to -$94.3M in 2024. The lack of revenue and increasing losses limit the assessment of profitability and growth metrics, resulting in a lower score.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating a solid financial structure. The debt-to-equity ratio remains low due to minimal debt, demonstrating conservative leverage. However, the lack of revenue generation could pose future financial risks if cash reserves diminish without revenue inflow.

Cash Flow

Astria Therapeutics has negative operating cash flow, which is expected in a pre-revenue biotech company. Despite the negative free cash flow, the company has managed cash inflow through financing activities, maintaining adequate cash reserves. The operating cash flow to net income ratio suggests challenges in generating cash relative to reported net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-131.42M	-94.26M	-83.03M	-53.50M	-194.98M	-37.44M
Net Income	-116.92M	-94.26M	-72.89M	-51.83M	-194.91M	-37.30M
Balance Sheet
Total Assets	281.92M	342.36M	254.67M	230.63M	127.51M	47.46M
Cash, Cash Equivalents and Short-Term Investments	259.18M	328.13M	246.53M	226.44M	125.51M	44.93M
Total Debt	4.77M	5.35M	329.00K	939.00K	365.00K	1.05M
Total Liabilities	21.41M	23.10M	11.55M	9.42M	5.20M	6.79M
Stockholders Equity	260.51M	319.26M	243.12M	221.22M	122.31M	40.67M
Cash Flow
Free Cash Flow	-116.01M	-81.54M	-68.47M	-43.62M	-30.17M	-32.52M
Operating Cash Flow	-115.40M	-81.21M	-68.44M	-43.53M	-30.15M	-32.48M
Investing Cash Flow	89.05M	-191.86M	135.05M	-167.13M	-12.55M	6.30M
Financing Cash Flow	15.30M	157.20M	88.40M	144.72M	104.28M	40.86M

Astria Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXS, the sentiment is Positive. The current price of 6.76 is above the 20-day moving average (MA) of 6.64, above the 50-day MA of 6.19, and below the 200-day MA of 7.01, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 54.92 is Neutral, neither overbought nor oversold. The STOCH value of 61.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXS.

Astria Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$438.36M	―	-51.84%	―	-100.00%	-25.75%
PVLA	52 Neutral	$509.67M	―	-68.21%	―	-97.15%	54.85%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
AVIR	47 Neutral	$276.96M	―	-32.38%	―	―	23.24%
ATXS	44 Neutral	$375.29M	―	-38.49%	―	―	11.81%
HUMA	42 Neutral	$284.28M	―	-257.38%	―	―	63.92%
CADL	33 Underperform	$322.08M	―	-55.18%	―	―	-2.93%

Astria Therapeutics Corporate Events

Astria Therapeutics Unveils Phase 3 Trial for Navenibart

Astria Therapeutics has announced the design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema, which will feature both every 3- and 6-month treatment arms. This trial aims to support global registration and is expected to initiate in Q1 2025. The company is pioneering flexible dosing options to potentially make navenibart a market-leading choice for HAE therapy, and the trial design incorporates feedback from regulatory authorities and collaboration with patients and physicians.